Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 Equity-to-Asset is 0.74 as of Jun. 2026. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, BillionToOne ranks better than 72.86% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BillionToOne's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $536.8 Mil. BillionToOne's Total Assets for the quarter that ended in Jun. 2026 was $729.7 Mil.
Therefore, BillionToOne's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.74.
The historical rank and industry rank for BillionToOne's Equity-to-Asset or its related term are showing as below:
BLLN'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.14 Med: -0.73 Max: 0.76
Current: 0.74
During the past 3 years, the highest Equity to Asset Ratio of BillionToOne was 0.76. The lowest was -1.14. And the median was -0.73.
BLLN's Equity-to-Asset is ranked better than 72.86% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs BLLN: 0.74
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BillionToOne Equity-to-Asset Related Terms
BillionToOne Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BillionToOne's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLN vs TWST, SHC, RDNT: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, BillionToOne's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BillionToOne's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BillionToOne's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a Equity-to-Asset of 0.74 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #57 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 27.1%.
Is BillionToOne's Equity-to-Asset too high?
BillionToOne's current Equity-to-Asset is 0.74. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. BillionToOne's value of 0.74 is 24.4% above this industry median. Based on the distribution chart, BillionToOne ranks #57 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Equity-to-Asset compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #57 out of 210 companies for Equity-to-Asset. This puts BillionToOne in the upper half of its industry. The industry median Equity-to-Asset is 0.60. BillionToOne's value of 0.74 is 24.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Equity-to-Asset of 0.74 is 24.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Equity-to-Asset is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Equity-to-Asset of 0.74. The current Equity-to-Asset is 0.74 and 24.4% above the Medical Diagnostics & Research industry median of 0.60. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BillionToOne (BLLN), the current Equity-to-Asset is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
